Company Encyclopedia
View More
name
E Fund Hongkong Hang Seng Composite Small Cap Index Fund(LOF)-A
161124.SZ
News
View More

Meitu, Inc.'s (HKG:1357) 13% loss last week hit both individual investors who own 46% as well as institutions

Meitu, Inc. (HKG:1357) experienced a 13% stock price drop last week, affecting both retail investors, who hold 46% of shares, and institutions with 31% holdings. Retail investors have significant influence over company decisions. Insiders have been selling shares, and the top 17 shareholders control 50% of the company. CEO Zeyuan Wu is the largest shareholder with a 13% stake. The company's market cap is HK$34b, with insiders holding HK$7.8b worth of shares. Analysts suggest considering future growth prospects despite current warning signs.

Simplywall·
HK
01357
-0.80%
Simplywall·
HK
01357
-0.80%

ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances | AAPG Stock News

Ascentage Pharma presented promising data from a Phase Ib/II study of Lisaftoclax at the ASH 2025. The study showed Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% ORR. It achieved an 80% ORR in newly diagnosed high-risk MDS/CMML, with a strong safety profile. The results highlight Lisaftoclax's therapeutic potential and distinct clinical value, aiming to address unmet needs in myeloid malignancies.

StockTitan·
HK
06855
-2.05%
US
AAPG
+7.10%
StockTitan·
HK
06855
-2.05%
US
AAPG
+7.10%

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting | AAPG Stock News

Ascentage Pharma presented pivotal study data for Lisaftoclax at the 2025 ASH Annual Meeting, demonstrating significant efficacy and safety in BTK-refractory CLL/SLL patients. Lisaftoclax achieved a 62.5% ORR and a median progression-free survival of 23.89 months, with no tumor lysis syndrome reported. The study supports Lisaftoclax's NDA approval in China and highlights its potential as a breakthrough therapy for high-risk CLL/SLL patients.

StockTitan·
HK
06855
-2.05%
US
AAPG
+7.10%
StockTitan·
HK
06855
-2.05%
US
AAPG
+7.10%

Top 10 HK Stock Gainers (12.5)

ZCLOUD TECH CON(09900) rose 9.92%, with a trading turnover 19.9 Million HKD, and a year-to-date rose 308.6%. QUNABOX GROUP(00917) rose 7.95%, with a trading turnover 86.7 Million HKD, and a year-to-date fell 48.2%. DEEWIN(02418) rose 7.69%, with a trading turnover 26.0 Million HKD, and a year-to-date rose 656.3%.

LB Select·
HK
09900
+2.11%
HK
00917
-2.81%
HK
02418
-4.98%
LB Select·
HK
09900
+2.11%
HK
00917
-2.81%
HK
02418
-4.98%

Qunabox rises on deal with Dubai Ruling Family for AI platform development

Qunabox Group's shares surged 10.4% to HK$34.98 following a strategic partnership with His Highness Shaikh Thani Saeed Thani Juma Al Maktoum from the Dubai Ruling Family. They will co-develop HOLOX, an AI platform for gaming and entertainment, aligning with UAE's AI Strategy 2031. Despite this rise, the stock is down 49.5% YTD, while the Hang Seng TECH Index is up 24.4%.

Reuters·
HK
00917
-2.81%
Reuters·
HK
00917
-2.81%
© 2025 Longbridge｜Disclaimer